News | March 10, 2026
Hopewell Therapeutics sublicenses breakthrough LNP technology to Foxcroft for cancer vaccine development
The two companies will collaborate to evaluate Hopewell’s ttLNPs for clinical applications
The two companies will collaborate to evaluate Hopewell’s ttLNPs for clinical applications
The company says those insights can power advanced analytics and real-world evidence (RWE), helping researchers improve trial design, study feasibility, and recruitment strategies
The company announced positive topline data from the Phase II ZUPREME-1 trial
The licensed intellectual property covers methods and designs for CAR constructs engineered to function in myeloid cell populations
Strong performances in its Life Science, Healthcare and Electronics divisions — particularly Process Solutions, Cardiovascular treatments and Semiconductor Materials — powered the company’s results
Hyderabad emerged as Lonza’s preferred destination after an extensive global evaluation process
Pivya is Alembic’s first branded pharmaceutica product in the US and is being marketed through Alembic Therapeutics LLC
Moderna will appeal to the Federal Circuit to assert that its government-contractor immunity limits liability under federal law
Built on the Percept Platform and enhanced with BrainSense technology, the system can adjust stimulation levels in real time, responding to brain signals without manual intervention
Subscribe To Our Newsletter & Stay Updated
